385 BioNTech says in its annual report to the US Securities and Exchange Commission that the efficacy of its current mRNA Corona vaccine may not be sufficient for permanent regulatory approval. (media.greatawakening.win) posted 2 years ago by purkiss80 2 years ago by purkiss80 +386 / -1 27 comments download share 27 comments share download save hide report block hide replies
The next point is even more mind blowing - “Significant adverse reactions may occur during our clinical trials…” They don’t sound very confident of getting approval at all.